Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely [Seeking Alpha]
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Seeking Alpha
The company plans to initiate a Phase 3 study of bexicaserin and hopes to release data from an open-label extension study later this year. Longboard's financials show increased R&D and G&A expenses, but with a potential approval for bexicaserin in play, the company's market cap has risen to over $725m. After a 300% gain in the stock price in recent months, I am not sure there are enough catalysts in play to support further upside in 2024, although the company's second lead candidate, the S1P modulator LP659, is worth keeping an eye on. Investment Overview In a note for Seeking Alpha in May last year, I gave Longboard Pharmaceuticals ( NASDAQ: LBPH ) a "Buy" recommendation, citing upcoming data catalysts for the company's two clinical stage assets - the 5-HT2C Superagonist LP352, now known as bexicaserin, being developed to treat developmental and epileptic encephalopathies (DEEs), and LP659 - and a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 [Yahoo! Finance]Yahoo! Finance
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15Business Wire
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
LBPH
Earnings
- 11/2/23 - Beat
LBPH
Sec Filings
- 4/15/24 - Form 8-K
- 4/12/24 - Form ARS
- 4/12/24 - Form DEFA14A
- LBPH's page on the SEC website